

PetMedix enters into antibody discovery collaboration with Zoetis

Embargoed until January 7th — Cambridge (UK), January 7th, 2022

PetMedix™ is pleased to announce a collaboration with Zoetis to develop novel, fully species-specific companion animal monoclonal antibody therapeutics (mAbs) using PetMedix's proprietary transgenic platforms. As part of the collaboration, PetMedix will undertake discovery activities against a number of key targets, and Zoetis has an exclusive option to develop and bring these therapies to market.

Having brought three novel mAbs to market to date, Zoetis is a leader in companion animal antibody therapeutics, including fully species-specific antibodies. Their end-to-end research and development expertise in veterinary antibody therapeutics coupled with their manufacturing, sales and marketing scale and success makes them a strong partner for PetMedix. This is well complemented by PetMedix's strengths in antibody discovery, thanks to the combination of its proprietary transgenic platforms and its team of nearly 50 world-class scientists at its labs in Cambridge, UK.

“We are excited to be partnering with Zoetis. Bringing together our unique pet antibody discovery engine with their proven ability to not just develop antibodies, but also make them a commercial success, is set to be a winning combination. PetMedix's mission is to elevate expectations in pet care, and we feel that this collaboration is another step towards that.” – Dr Tom Weaver, CEO PetMedix.

While there are many technologies that have been used to develop human therapeutic antibodies, 40 years of research has shown the benefits of antibodies that are 100% species-matched to the patient. Of the two most prevalent technologies to develop fully human antibodies, transgenic rodent platforms and phage display, the transgenic-based methods have yielded many more approved therapeutics in spite of being the newer technology¹. Monoclonal antibodies from transgenic platforms have also been significantly more commercially successful in human medicine, with ten transgenic mAbs exceeding \$1B in sales in 2020, compared to just two phage mAbs in the same period².

PetMedix is looking to build on this success for companion animals. Its Ky9™ and Felyne™ platforms are designed in the same way as the gold-standard human transgenic platforms, such as the IntelliSelect™ platform of Kymab (now a Sanofi company) and the Velocimmune™ platform of Regeneron. This discovery collaboration with PetMedix also marks the third publicly announced deal that Zoetis has done with companies using transgenic platforms for antibody discovery, with PetMedix providing a novel technology designed specifically for canine and feline antibodies.

“At Zoetis, we are committed to continuing our leadership to develop and discover new therapeutic antibodies that can help pets live longer, healthier lives. Collaborating with

¹ <https://www.antibodysociety.org/resources/approved-antibodies/>

² <https://www.understandinganimalresearch.org.uk/news/antibodies-factsheet/>

PetMedix complements our own research and development activities, and we are pleased to be working with them to explore areas of unmet clinical needs in pets.” – Robert J. Polzer, Executive Vice President and President, Research and Development at Zoetis.

This collaboration, alongside the one announced in January 2021 with Boehringer Ingelheim Animal Health, form part of PetMedix’s long term strategy for bringing transformative new therapies to market. PetMedix has an extensive internal pipeline, discovered in house using its proprietary platforms, and is looking ahead at the best routes to get these novel medicines into the hands of veterinarians.

Dr Fabian Kausche, PetMedix Chair, commented on the importance of this deal for the company’s longer-term ambitions, “Our partnering strategy is to work with the best and most experienced animal health corporates in order to develop the close relationships that will form the basis of PetMedix’s future success. These deals have been structured to demonstrate to our partners the quality of the platforms we have created and the antibodies they can produce, whilst retaining full independence with our internal pipeline and its numerous assets.”

...ENDS

About PetMedix™

PetMedix™ is a Cambridge, UK, based research and development stage biopharmaceutical company developing antibody-based therapeutics for companion animals. The growing team have over 30 years’ experience building platforms that can develop species-specific therapeutic antibodies.

Driven by the core value of elevating expectations in pet care, PetMedix™ is taking the cutting edge of human medicine and using it to develop innovative new veterinary treatments against a wide range of clinical indications for dogs and for cats. Find out more about the science of antibody innovation at www.petmedix.com and connect with us on [Twitter](#), [LinkedIn](#), [Facebook](#) and [Instagram](#).

About Zoetis

As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After nearly 70 years innovating ways to predict, prevent, detect, and treat animal illness, Zoetis continues to stand by those raising and caring for animals worldwide -- from livestock farmers to veterinarians and pet owners. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of \$6.7 billion in 2020 with approximately 11,300 employees. For more information, visit www.zoetis.com.